| Symbol | BCAB |
|---|---|
| Name | BIOATLA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 11085 TORREYANA ROAD, SAN DIEGO, California, 92121, United States |
| Telephone | +1 858 558-0708 |
| Fax | — |
| — | |
| Website | https://www.bioatla.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs. Additional info from NASDAQ: |
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Read moreNew Form S-8 - BioAtla, Inc. <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0001193125-26-134492 <b>Size:</b> 847 KB
Read moreNew Form 10-K - BioAtla, Inc. <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0001193125-26-134499 <b>Size:</b> 11 MB
Read moreNew Form 424B2 - BioAtla, Inc. <b>Filed:</b> 2026-03-13 <b>AccNo:</b> 0001539497-26-000924 <b>Size:</b> 107 KB
Read moreSievers Eric 🟢 acquired 240.0K shares of BioAtla, Inc. (BCAB) Transaction Date: Mar 10, 2026 | Filing ID: 104136
Read moreSHORT JAY M PHD 🟢 acquired 430.0K shares of BioAtla, Inc. (BCAB) Transaction Date: Mar 11, 2026 | Filing ID: 104134
Read moreVasquez Christian 🟢 acquired 240.0K shares of BioAtla, Inc. (BCAB) Transaction Date: Mar 10, 2026 | Filing ID: 104132
Read moreSHORT JAY M PHD 🔴 sold 7.7K shares of BioAtla, Inc. (BCAB) at $0.25 Transaction Date: Feb 28, 2026 | Filing ID: 085971
Read more| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| BA3182 | DRUG | Phase PHASE1 | Advanced Adenocarcinoma | RECRUITING | NCT05808634 |
| Cetuximab | BIOLOGICAL | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT05271604 |
| Evalstotug (BA3071) | BIOLOGICAL | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT05271604 |
| Ozuriftamab Vedotin | BIOLOGICAL | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT05271604 |
| Pemetrexed (Alimta) | DRUG | Phase PHASE1 | NSCLC | ACTIVE_NOT_RECRUITING | NCT05180799 |
| Pembrolizumab | BIOLOGICAL | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT05271604 |
| Nivolumab | BIOLOGICAL | Phase PHASE1 | NSCLC | ACTIVE_NOT_RECRUITING | NCT05180799 |
| BA3071 | BIOLOGICAL | Phase PHASE1 | NSCLC | ACTIVE_NOT_RECRUITING | NCT05180799 |
| Toripalimab | DRUG | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| ENB003 | DRUG | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| BA3021 | DRUG | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| BA3011 | DRUG | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| Durvalumab | DRUG | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| CAB-ROR2-ADC | BIOLOGICAL | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT03504488 |
| PD-1 inhibitor | BIOLOGICAL | Phase PHASE2 | Non-Small-Cell Lung Cancer | COMPLETED | NCT04681131 |
| CAB-AXL-ADC | BIOLOGICAL | Phase PHASE2 | Non-Small-Cell Lung Cancer | COMPLETED | NCT04681131 |